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Background:Whereas intense physical activity has been associated with deleterious effects on elite athletes’ health, in particular
due to cardiovascular anomalies, long-term follow-ups have suggested lower mortality rates among elite athletes. Causes of
death for French Olympic athletes and female elite athletes have not been studied.
Hypothesis/Purpose: We aimed to measure overall and disease-specific mortality of French female and male Olympians compared
with the French general population. We hypothesize that Olympians, both women and men, have lower mortality rates.
Study Design: Cohort study; Level of evidence, 3.
Methods: French elite athletes (601 women and 1802 men) participating in summer or winter Olympic Games from 1948 to 2010
had their vital status verified by national sources and were followed until 2013. Causes of death were obtained via the National
Death registry from 1968 to 2012. Overall and disease-specific mortalities of Olympians were compared with those of the French
general population through standardized mortality ratios (SMRs) and 95% CIs. Olympians’ observed and expected survivals were
illustrated by Kaplan-Meier curves.
Results: At the endpoint of the study, 13 women and 222 men had died. Overall mortality in Olympians compared with that of
their compatriots was 51% lower (SMR, 0.49; 95% CI, 0.26-0.85) among women and 49% lower (SMR, 0.51; 95% CI, 0.45-
0.59) among men. Olympic athletes’ survival is significantly superior to that of the French general population (women, P = .03;
men, P\ .001). According to the total deaths occurring from 1968 to 2012 (12 among women, 202 among men), female Olym-
pians died from neoplasm (50.0%), external causes (33.3%), and cardiovascular diseases (16.6%). The main causes of death
among men were related to neoplasms (36.1%), cardiovascular diseases (24.3%), and external causes (14.4%). Regarding the
main causes of mortality among male Olympic athletes, the SMRs were as follows: 0.55 for neoplasms (95% CI, 0.43-0.69),
0.55 for cardiovascular diseases (95% CI, 0.41-0.73), and 0.66 for external causes (95% CI, 0.44-0.94).
Conclusion: French Olympians live longer than their compatriots: A lower overall mortality of similar magnitude is observed
among male and female athletes compared with the general population. The main causes of death in French Olympians are neo-
plasms, cardiovascular diseases, and external causes.
Keywords: overall mortality; disease-specific mortality; elite athletes; epidemiology
Participants in the Olympic Games are a specific popula-
tion owing to the selection process they undergo. Olympic
athletes are the best competitors from each country, ath-
letes who demonstrate rare physiological aptness and
physical traits,4 suggesting athletic predispositions (both
genetic and environmental)36 and high levels of training
for long periods.16
Sport-related risks expose Olympians to specific out-
comes: These athletes possibly have higher mortality due
to cardiovascular anomalies,8,26,35 neurologic sequelae
resulting from recurrent concussions in some disci-
plines,17,21 or use of doping agents.6,29 In addition, high
forces in certain sports may increase the probability of
fatal events due to accidents and collisions.9,11
However, a recent meta-analysis on athletes’ mortality
evidenced that elite athletes live longer than their compa-
triots.14 French Olympians were not part of the cohorts
included in those studies. In addition, there is a lack of
studies considering female athletes, and very few studies
have analyzed athletes’ causes of deaths or submitted vital
status to national certification.
We aimed to assess the overall and cause-specific mor-
tality of female and male French Olympic athletes
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compared with their compatriots in the French general
population. We hypothesized that French Olympians,
both women and men, will have a lower mortality.
METHODS
Study Design
Retrospective cohort study of French male and female
Olympians.
Participants
The study cohort consisted of all women and men who rep-
resented France in the summer or winter Olympic Games
after World War II—from 1948 up to 2010—and whose
vital status was validated by the National Registry of Iden-
tification of Physical Persons (RNIPP).
Data Collection
All French athletes participating in at least 1 Olympic
Games from 1948 up to 2010 were identified. Their bio-
graphical information came from reliable historians’ sour-
ces.5 These data were compared and confirmed with data
from the International Olympic Committee (Olympic.org)
and data from each official website of international federa-
tions that archive athletes’ biographies.
The identity information and vital status of the study
athletes were obtained from 1948 up to January 1, 2013
(study endpoint) via the RNIPP from the National Insti-
tute of Statistics and Economical Studies (INSEE), which
inventories life status of French citizens living in or out
of the French territory. Vital status was also followed up
for Olympians who were born abroad but competed in the
Olympic Games for France, as well as Olympians who emi-
grated. Subjects who could not have their vital status prop-
erly certified by national sources were not included in the
study (Figure 1). Such exclusions were homogeneous dur-
ing the studied period for both sexes.
The cause of death of each deceased subject was
obtained from the Centre for epidemiology on medical
causes of death (Ce´piDc), which has registered the causes
of all deaths occurring in French territory since 1968.
Causes of death occurring abroad or before 1968 or in
2012 and later were not currently accessible due a 2-year
lag between the availability of death status and its corre-
sponding cause. Therefore, the cohorts’ causes of death
were obtained from 1968 up to January 1, 2012 (Figure
1). The vital status of Olympians who died abroad was
identified even though the cause of their death could not
be accessed.
This study was approved by the Advisory Committee on
Information Processing in Research in the Field of Health
(CCTIRS) and the French National Commission for Data
Protection and Liberties (CNIL).
Statistical Analysis
Descriptive analyses of the study cohort were expressed as
means (6SD) and proportions (%) when suitable. We com-
pared the mortality of French Olympic athletes with that
of the French general population using two methods: (1)
overall and disease-specific standard mortality ratio
(SMR) and its 95% confidence interval14 and (2) Kaplan-
Meier curves to illustrate the observed and the expected
survival rate of Olympians.33
The SMR allows comparison of the mortality of the stud-
ied cohort with that of the total population containing this
cohort,22 with age and period adjustment. In practical terms,
SMR is the ratio between the number of deaths observed in
the Olympic cohort and the number of expected deaths if
the Olympians had the same death rates as the French pop-
ulation. Death rates of the general population were assessed
via Ce´piDc. Individuals in a cohort differ in the time of risk
exposure along their follow-up. Hence, Olympian person-
year was calculated, which was defined as the actual time
at risk, in years, of Olympians’ follow-up. Therefore, the
SMR denominator was calculated by multiplying French
death rates by the Olympian person-years for the correspond-
ing age group and period for each sex. Time was categorized
in 1-year intervals from 1948 to 2013. Age groups were calcu-
lated by 5-year intervals from 15-19 years up to 100-104
years. The study athletes’ follow-up started with the date of
their first participation in the Olympic Games and finished
with their date of death (if concerned) or with the study end-
point. An SMR equal to 1.0 means that the number of
observed deaths equals that of expected cases. If lower than
1.0, the SMR indicates a lower mortality of Olympians com-
pared with the general population. The 95% confidence inter-
vals were calculated using the exact method.22
The Kaplan-Meier expected survival was based on the
French general population death rates, and the difference
with the Olympic athletes’ observed survival was assessed
through the log-rank test.31 P values of\.05 were consid-
ered to indicate statistical significance for all analyses.
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Scenario
To address subjects who were excluded from the study due
to absence of vital status official validation, we recalcu-
lated overall SMR analyses, adding all the Olympians
who had been excluded (Figure 1). We performed overall
mortality analyses assuming as true the vital status from
sources monitoring Olympians’ deaths (every official inter-
national federation’s website and Olympic historian
sources).5
Disease-Specific Mortality
To determine the disease-specific mortality, we compared
each cause of death found among Olympians with the spe-
cific mortality rate of the general population by calculating
SMRs for the available period, 1968 to 2012. Causes of
deaths were classified according to the International Clas-
sification of Diseases (ICD) (8th revision before 1978, 9th
revision between 1979 and 1999, 10th revision after 2000).
Age Effect
To analyze age-dependent differences in Olympians’ mor-
tality, SMR values were grouped according to 10-year age
intervals from 25-34 up to 85-94 years. Age groups younger
than 25 years or older than 95 years were not studied
because they accounted for only 2 deaths among women
and men. R software v2.14.0 was used for the analysis.
RESULTS
Overall Mortality
The analyses were performed on 601 female and 1802 male
French Olympians whose vital status was validated by
national sources. Among those, 235 (n = 13 women; n =
222 men) died before the study endpoint. The characteris-
tics of the study cohort are presented in Table 1. The mean
(SD) follow-up time for Olympians who were alive was 20.3
years (614.6) for women and 26.8 (616.7) for men. For
those who died, the follow-up time was 35.5 years
(617.4) for women and 43.7 (613.5) for men. The overall
SMR results were 0.49 (95% CI, 0.26-0.85, P = .007) for
female Olympians and 0.51 (95% CI, 0.45-0.59, P\ .001)
for male Olympians.
Scenario
The analyses were performed adding 125 women and 284
men whose vital status was identified by nonofficial sour-
ces, totaling 726 female and 2086 male French Olympians.
Among those, 280 (n = 16 women; n = 264 men) had a date
of death known before the study endpoint. This scenario
French athletes in the Olympic Games, 1948-2010
 F:  n = 831 M:  n = 2582 
Assessed for eligibility
Olympians included and verified by the RNIPP
F:  n = 726 (88.3%)            M:  n = 2086 (80.8%)
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F: n = 105 (12.6%)   M:  n = 496 (19.2%)
Total included - available for overall mortality analysis
Olympians validated by the RNIPP
F:  n = 601 (82.8%)            M:  n = 1802 (86.4%)  
Alive as of
January 1, 2013
F:  n =  588 (97.8%)
M:  n = 1580 (87.7%) 
Deceased as of
January 1, 2013
F:  n = 13 (2.2%)
M:  n = 222 (12.3%) 
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Cause of death 
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Figure 1. Flow diagram for overall and disease-specific mortality follow-up among the study cohort of female (F) and male (M)
French Olympic athletes. Ce´piDc, Centre for epidemiology on medical causes of death; RNIPP, National Registry of Identification
of Physical Persons.
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shows a significantly lower mortality in female (SMR, 0.38;
95% CI, 0.22-0.62, P\ .001) and male (SMR, 0.51; 95% CI,
0.45-0.57, P \ .001) Olympians than in the general
population.
Survival Estimations
The observed and expected survival curves for female and
male Olympians are illustrated in Figure 2. Olympians’
observed curve is significantly different from the expected
curve derived from the matched general French population
for women (P = .03) and men (P\ .001). The men’s observed
curve diverges and shifts to the right early in the follow-up
period and narrows the gap at the end of the follow-up. The
women’s observed curve separates later from the expected
curve and is clearly superior only at the end of the follow-up.
Causes of Death
Among all deaths observed (n = 235), 1 woman and 14 men
died after 2012. Nobody died before 1968. Among women,
the causes of all deaths that occurred during the available
identification period were identified. Concerning men, the
cause of death was identified for 202 men; 6 men died
abroad and their causes of deaths could not be established.
The SMR results are represented for each cause of
death identified among female and male Olympians (Fig-
ure 3). The 3 causes of death observed among women
were neoplasm (50.0%), external causes (33.3%), and car-
diovascular diseases (16.6%), without significant differen-
ces with the general population.
The main causes of death among men were neoplasms
(36.1%; SMR, 0.55 [95% CI, 0.43-0.69]), cardiovascular dis-
eases (24.3%; SMR, 0.55 [95% CI, 0.41-0.73]), and external
causes (14.4%; SMR, 0.66 [95% CI, 0.44-0.94]). The mortal-
ity rates for these causes and for those due to mental dis-
orders, respiratory system diseases, endocrine or
nutritional diseases, and digestive system diseases were
significantly lower for Olympians compared with their
compatriots (Figure 3).
Mortality by Age Group
A significantly lower mortality rate was observed among
male Olympians from the 25-34 to the 75-84 age groups
compared with the general population (Figure 4). The
lowest mortality was seen among the youngest group
(SMR, 0.19; 95% CI, 0.05-0.48). Olympians older than 85
years did not show a significant mortality difference
(SMR, 0.90; 95% CI, 0.60-1.30). The lower mortality rate
in younger Olympians is based on a larger subcohort size
for younger athletes than for older ones, as represented by
the decreased percentage of persons-years with age (Figure
4). No significant differences with the general population
were observed for age groups among female Olympians.
DISCUSSION
Mortality in Female Olympians
Our study shows a 51% lower mortality among female
Olympians compared with their referents in the French
population. To the best of our knowledge, this is the first
study that evidences female athletes’ lower mortality com-
pared with the general population based on national certi-
fied vital status.
The lower risk of all-cause mortality found among female
Olympians is similar to that of male Olympians: Both dem-
onstrate a large survival advantage over their compatriots.
Such findings highlight that male and female elite athletes
share common determinants to a greater longevity, such as
a predisposition to achieve elite athletic status and possibly
the training and lifestyle required by Olympic participation.
The survival advantage experienced by French Olympians
reinforces findings of previous studies showing higher lon-
gevity among elite athletes.1,3,10,14
However, the Kaplan-Meier curves among women show
a different dynamic from that of male Olympians, as wom-
en’s advantage over the general population occurs later in
life. Their survival deviates further from that of the gen-
eral population at the end of the follow-up. That means
that of the small sample of women who could be followed
up beyond 60 years of age, most are still alive. Probably
the advantage elite female athletes already show will
widen in case of a longer follow-up.
Also singular is the narrowing between survival curves
at the beginning of the women’s follow-up. We expected to
find a survival dynamic similar to that displayed among
male Olympians, for whom the survival advantage starts
with their Olympic participation—due to the cohort selec-
tion effect.18 The few deaths occurring among young
women could explain such narrowing, even though the
mortality analysis by age groups does not show any signif-
icant difference by age.
Women’s disease-specific mortality also presents a partic-
ularity regarding the external causes of deaths (which com-
prise deaths from accidents, falls, homicides, and suicides).
Whereas the main causes of deaths observed in male Olym-
pians have analogous proportions to the main causes in the
general population, the external causes among female
Olympians are in larger proportions than in the general
population. Nevertheless, no mortality difference by specific
cause of death was shown among women.
Our results, based on very few deaths, certainly give
rise to limited interpretation and analysis. Hence, the
TABLE 1
Cohort of French Olympic Athletes, 1948-2013
Characteristic
Women
(n = 601)
Men
(n = 1802)
No. of person-years 12,075.6 51,170.3
Age at study entry, y, mean 6 SD 23.3 (64.6) 25.2 (64.6)
Birth year range 1920-1992 1905-1991
Death year range 1986-2012 1973-2012
Age range at study endpoint, y
Alive 21-92 22-94
Deceased 23-92 26-95
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findings regarding women’s survival dynamics, age depen-
dence, and disease-specific mortality reveal a path requir-
ing further investigation. Yet this is the largest cohort of
elite sportswomen ever followed up, corresponding to 85%
of all cohorts of sportswomen accounted for in a recent
meta-analysis,14 and it provides evidence of higher longev-
ity among French female Olympians.
Mortality in Male Olympians
We found consistently lower mortality rates for male
Olympians versus their male compatriots until advanced
ages. The risk of all-cause mortality among men by age
group varies from 81% lower at younger ages to 27% lower
in the 75- to 84-year age group, and there is no difference
with the general population at 85 years of age or older.
Such age-related mortality patterns could be due to a sur-
vival selection process. At younger ages, Olympians are at
the maximum of their capacity.4 With aging a selection
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Figure 2. Observed and expected survival curves for French (A) female and (B) male Olympic athletes. The observed survival rate
is represented by the solid black curve and its dashed confidence interval. The gray curve refers to the expected survival rate
derived from the matched general French population.
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Figure 3. Disease-specific mortality of French Olympic ath-
letes from 1968 to 2012. Cause of death was classified
according to the International Classification of Diseases
(8th revision before 1978, 9th revision between 1979 and
1999, 10th revision after 2000). The vertical bold line repre-
sents the general population reference value (standard mor-
tality ratio [SMR] = 1). The causes of death that were
significantly different from those of the general population
are in bold. (a) P\ .001; (b) P\ .01; (c) P\ .05.
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Figure 4. Overall standardized mortality ratios (SMRs) and
95% confidence intervals by 10-year age intervals for French
athletes participating in the Olympic Games from 1948 to
2010. The horizontal line represents the general population
reference value (SMR = 1). The dashed line represents the
percentage of person-years followed.
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also operates in the general population, and at very
advanced ages both groups include highly selected individ-
uals. A study comparing Olympians to supercentenarians
shows that among worldwide participants in the Olympic
Games since 1896, none has lived to 110 years.2 Olympians
live longer but are not the longest-lived.
The overall mortality found among male Olympians is
mainly associated with lower risk of 3 major causes of
deaths seen among them: neoplasms, cardiovascular dis-
eases, and external causes (which are 34%-45% lower
than those found in the general population). In addition,
French male Olympians display a significantly lower mor-
tality from mental disorders, endocrine or nutritional dis-
eases, and digestive system diseases and an 85% lower
risk of mortality due to respiratory system diseases. The
mortality from other causes is not statistically different
from that of the general population. Rare causes of death,
however, are based on a few deaths only, resulting in large
confidence intervals that are hardly interpretable.
The benefits of moderate physical activity are well known
for preventing cardiovascular problems.45 Intense training,
however, has been associated with cardiovascular events:
coronary remodeling,7 artery calcification,25 and atrial fibril-
lation and flutter,26 although an association has not been
clearly established.20,38 A triggered arrhythmia threshold
has been proposed,8 but the 1500 lifetime hours of intense
exercise are largely exceeded by Olympic athletes.16 Hence,
a U-shape curve has been proposed for elite athletes, relating
training load and cardiovascular risk.35
Here we show a 45% lower mortality from cardiovascular
diseases among male Olympians compared with the general
male population. This long-term outcome for French Olym-
pians is consistent with previous findings.3,24,39 Indeed, a 4-
to 17-year follow-up of Italian Olympians did not show any
deterioration in left ventricular function or an increased
rate of cardiovascular events.30 There is growing evidence
that the cardiovascular benefits of practicing sports at an
elite level outweigh potential negative effects.14,20,37 These
elements may suggest another association between health
effect and exercise load: an L-shape for the relation between
risk and exercise, where there is no risk resurgence at the
highest exercising levels for previously healthy subjects.
These results, however, should be interpreted in light of
the heterogeneity of sports within the cohort, given that we
sampled a wide range of athletes participating in activities
from pure anaerobic to fully aerobic sports.
A two-way relation is possibly operating among Olym-
pians: Rare traits enable high-level sport practice, and
high-level sport conditions maintain capacities that reduce
cardiac and overall mortality.
Cohort Selection Effect
Performance selection processes result in selecting healthy
subjects who are in a favorable environment and have
genetic predispositions.44 Olympians constitute the fittest
athletes who have a highly unusual set of physical and psy-
chological traits.32,40 The presence of genotypes related to
lower disease risk among elite athletes has been
debated.15,46 The Olympians’ survival advantage affects
individuals who have undergone an inevitable selection
process. It therefore needs to be cautiously interpreted,
because this advantage may not be extendable to the gen-
eral population. In other studies, highly selected male
cohorts showed comparably low overall mortality, includ-
ing in comparison with healthy references.13,39 The com-
parison of Olympians with their compatriots reveals the
effect of a phenotypic selection on death rates. The rela-
tively lower mortality found is certainly enhanced by the
existence of chronically ill subjects in the reference popula-
tion. This situation is symmetrical to the selection of a con-
trol group in clinical studies of rare polygenic diseases.32
Health-Enhancing Physical Activity
Dose-response relations between training intensity and
health benefits are not well established,28,34,35 but the
overexposure to high-level training does not seem to be del-
eterious to French Olympians. This suggests that elite ath-
letes are probably capable of adapting to intense activity27
and still derive benefits from it, at least in terms of longev-
ity. Intense sports participation has nonetheless been asso-
ciated with increased risk of musculoskeletal and
connective tissue diseases.42 Even if such risk does not
seem to affect survival rates—here only 2 deaths were
related to musculoskeletal diseases—it remains unclear
whether Olympians’ higher longevity is associated with
higher morbidities and to what extent the presence of mor-
bidities may affect their quality of life.
No significant excess death was observed for any spe-
cific cause, in contrast with previous findings of higher
mortality due to amyotrophic lateral sclerosis among Ital-
ian soccer players,41 neurodegenerative diseases among
American football players,21 and suicide among Swedish
power sport athletes.23
The lowest mortality age group corresponds to the years
when most Olympians are still active, contrasting with the
higher mortality found during cyclists’ careers.24 Most
Olympians spend much of their training indoors or in con-
trolled outdoor environments, a safer condition than road
cycling, which may explain such divergence. Hence, it
seems that if sports are not directly unsafe, high-intensity
training does not provide further deleterious effects
throughout life on previously healthy people.
Maintaining a Healthy Lifestyle After a Sports Career
We have not assessed French elite athletes’ lifestyles after
their career. Previous studies, however, have reported that
athletes usually maintain healthier habits than the gen-
eral population before, during, and after their career,12
such as low smoking rates, good nutrition, and exercis-
ing.19 In addition, the Olympians’ level of fitness may con-
stitute a ‘‘health bank’’; this advantage may last over
years, as shown by the lower mortality across male Olym-
pians’ age groups. Human capacities decay with aging4 but
elite athletes start from a higher level. Hence, for a for-
merly well-trained person, physical activity may be effort-
lessly performed, allowing him or her to keep practicing
throughout life.19
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Use of Performance-Enhancing Substances
The use of substances designed to enhance athletic perfor-
mance is as old as the human aspiration to break limits,
and its use during the Olympics dates back to the first
Games.43 The first listing of prohibited substances was
made in the 1960s, but it has restricted doping only par-
tially; however, the adverse health-related effects of sub-
stances have been shown.6 We do not know which
athletes in our cohort used doping agents, and therefore
it is difficult to assess to what extent the use of such sub-
stances might have minimized the large survival benefit
experienced by French Olympic athletes.
Methodological Considerations
No causal inference can be made between Olympic partic-
ipation and the observed lower mortality of Olympians,
particularly because only age and period could be adjusted
for potential confounding factors. We simulated a scenario
to address the possible changes in our results that the
excluded athletes could cause. The lower mortality found
by adding excluded Olympians is similar to the outcomes
presented here, with similar results among men and
even lower mortality among women. Therefore, it is
unlikely that the athletes excluded from the study may
overturn the overall mortality results presented here.
Yet, we acknowledge a limitation with regard to the deaths
that occurred abroad or too recently for causes to be iden-
tified. Our method’s advantages rely on an extensive fol-
low-up of athletes of both sexes and of the highest
performance levels based on national vital status
certification.
Perspectives
Disease-specific studies assessing larger samples of elite
sportswomen are necessary to understand better the
causes of death that are associated with their lower overall
mortality. Analytical studies controlling the factors that
might influence elite athletes’ mortality are now required
to decipher this phenomenon: sport type, country, training
methods, performance level, biometrics, career period, dop-
ing practice, and postcareer lifestyle, including athletes’
quality of life.
CONCLUSION
French Olympians live longer than their compatriots: A
lower overall mortality of similar magnitude is observed
among sportswomen and sportsmen compared with their
compatriots. The main causes of death observed among
Olympians are neoplasms, cardiovascular diseases, and
external causes. These 3 major causes of death are signifi-
cantly lower among male Olympians than in the general
population. Studies based on larger cohorts of women elite
athletes are required for better comprehension of their sur-
vival advantage over their compatriots.
ACKNOWLEDGMENT
The authors thank Guillaume Sauliere for enhancing the
presentation of the figures. The authors thank the Insti-
tute National du Sport de l’Expertise et de la Performance
(INSEP) for its full support.
REFERENCES
1. Abel EL, Kruger ML. The healthy worker effect in major league base-
ball revisited. Res Sports Med Print. 2006;14(1):83-87.
2. Antero-Jacquemin JD, Berthelot G, Marck A, Noirez P, Latouche A,
Toussaint J-F. Learning from leaders: life-span trends in Olympians
and supercentenarians [published online August 20, 2014]. J Geron-
tol A Biol Sci Med Sci. doi:10.1093/gerona/glu130.
3. Antero-Jacquemin J, Desgorces FD, Dor F, et al. Row for your life:
a century of mortality follow-up of French Olympic rowers. PloS
One. 2014;9(11):e113362.
4. Berthelot G, Len S, Hellard P, et al. Exponential growth combined
with exponential decline explains lifetime performance evolution in
individual and human species. Age Dordr Neth. 2012;34(4):1001-
1009.
5. Clarke PM, Walter SJ, Hayen A, Mallon WJ, Heijmans J, Studdert
DM. Survival of the fittest: retrospective cohort study of the longevity
of Olympic medallists in the modern era. BMJ. 2012;345:e8308.
6. Deligiannis A, Bjo¨rnstad H, Carre F, et al. ESC study group of sports
cardiology position paper on adverse cardiovascular effects of dop-
ing in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13(5):687-694.
7. Ector J, Ganame J, Merwe N van der, et al. Reduced right ventricular
ejection fraction in endurance athletes presenting with ventricular
arrhythmias: a quantitative angiographic assessment. Eur Heart J.
2007;28(3):345-353.
8. Elosua R, Arquer A, Mont L, et al. Sport practice and the risk of lone atrial
fibrillation: a case-control study. Int J Cardiol. 2006;108(3):332-337.
9. Engebretsen L, Steffen K, Alonso JM, et al. Sports injuries and ill-
nesses during the Winter Olympic Games 2010. Br J Sports Med.
2010;44(11):772-780.
10. Fafian J. Mortality experience of National Basketball Association
players. North Am Actuar J. 1997;1(4):45-48.
11. Findling JE, Pelle KD. Encyclopedia of the Modern Olympic Move-
ment. Westport, CT: Greenwood Publishing Group; 2004:648.
12. Fogelholm M, Kaprio J, Sarna S. Healthy lifestyles of former Finnish
world class athletes. Med Sci Sports Exerc. 1994;26(2):224-229.
13. Gajewski AK, Poznan´ska A. Mortality of top athletes, actors and
clergy in Poland: 1924-2000 follow-up study of the long term effect
of physical activity. Eur J Epidemiol. 2008;23(5):335-340.
14. Garatachea N, Santos-Lozano A, Sanchis-Gomar F, et al. Elite ath-
letes live longer than the general population: a meta-analysis. Mayo
Clin Proc. 2014;89(9):1195-1200.
15. Go´mez-Gallego F, Ruiz JR, Buxens A, et al. Are elite endurance ath-
letes genetically predisposed to lower disease risk? Physiol
Genomics. 2010;41(1):82-90.
16. Gu¨llich A, Emrich E. Considering long-term sustainability in the devel-
opment of world class success. Eur J Sport Sci. 2014;14(suppl 1):
S383-S397.
17. Guskiewicz KM, Marshall SW, Bailes J, et al. Association between
recurrent concussion and late-life cognitive impairment in retired pro-
fessional football players. Neurosurgery 2005;57(4):719-726; discus-
sion 719-726.
18. John M. Last. A Dictionary of Epidemiology. 3rd ed. Oxford, UK:
Oxford University Press; 1995.
19. Kujala UM, Sarna S, Kaprio J, Tikkanen HO, Koskenvuo M. Natural
selection to sports, later physical activity habits, and coronary heart
disease. Br J Sports Med. 2000;34(6):445-449.
20. Kwok CS, Anderson SG, Myint PK, Mamas MA, Loke YK. Physical
activity and incidence of atrial fibrillation: a systematic review and
meta-analysis. Int J Cardiol. 2014;177(2):467-476.
Vol. 43, No. 6, 2015 Mortality in French Olympians, 1948-2013 1511
 at INSEP on May 25, 2016ajs.sagepub.comDownloaded from 
21. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative
causes of death among retired National Football League players.
Neurology. 2012;79(19):1970-1974.
22. Liddell FD. Simple exact analysis of the standardised mortality ratio.
J Epidemiol Comm Health. 1984;38(1):85-88.
23. Lindqvist A-S, Moberg T, Ehrnborg C, Eriksson BO, Fahlke C, Rose´n T.
Increased mortality rate and suicide in Swedish former elite male athletes
in power sports. Scand J Med Sci Sports. 2014;24(6):1000-1005.
24. Marijon E, Tafflet M, Antero-Jacquemin J, et al. Mortality of French
participants in the Tour de France (1947-2012). Eur Heart J.
2013;34(40):3145-3150.
25. Mo¨hlenkamp S, Lehmann N, Breuckmann F, et al. Running: the risk of
coronary events. Prevalence and prognostic relevance of coronary ath-
erosclerosis in marathon runners. Eur Heart J. 2008;29(15):1903-1910.
26. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk fac-
tor for atrial fibrillation and atrial flutter. Europace. 2009;11(1):11-17.
27. Noakes T, Spedding M. Olympics: Run for your life. Nature.
2012;487(7407):295-296.
28. O’Keefe JH, Lavie CJ. Run for your life . . . at a comfortable speed
and not too far. Heart. 2013;99(8):516-519.
29. Pa¨rssinen M, Kujala U, Vartiainen E, Sarna S, Seppa¨la¨ T. Increased
premature mortality of competitive powerlifters suspected to have
used anabolic agents. Int J Sports Med. 2000;21(3):225-227.
30. Pelliccia A, Kinoshita N, Pisicchio C, et al. Long-term clinical conse-
quences of intense, uninterrupted endurance training in Olympic ath-
letes. J Am Coll Cardiol. 2010;55(15):1619-1625.
31. Peto R, Peto J. Asymptotically efficient rank invariant test proce-
dures. J R Stat Soc Ser Gen. 1972;135(2):185.
32. Plomin R, Haworth CMA, Davis OSP. Common disorders are quanti-
tative traits. Nat Rev Genet. 2009;10(12):872-878.
33. Pohar M, Stare J. Relative survival analysis in R. Comput Methods
Programs Biomed. 2006;81(3):272-278.
34. Powell KE, Paluch AE, Blair SN. Physical activity for health: what
kind? How much? How intense? On top of what? Ann Rev Public
Health. 2011;32:349-365.
35. Predel H-G. Marathon run: cardiovascular adaptation and cardiovas-
cular risk. Eur Heart J. 2014;35(44):3091-3098.
36. Ruiz JR, Go´mez-Gallego F, Santiago C, et al. Is there an optimum
endurance polygenic profile? J Physiol. 2009;587(pt 7):1527-1534.
37. Sanchis-Gomar F, Garatachea N, Catala´n P, Lo´pez M, Lucia A, Ser-
rano-Osta´riz E. Strenuous endurance exercise and right ventricular
systolic function: no evidence of long-term sequelae. Int J Cardiol.
2015;179:297-298.
38. Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, Fiuza-Luces
C, Garatachea N, Lucia A. Strenuous exercise and the heart: are we
not seeing the wood for the trees? Int J Cardiol. 2014;176(3):
1304-1305.
39. Sarna S, Sahi T, Koskenvuo M, Kaprio J. Increased life expectancy of
world class male athletes. Med Sci Sports Exerc. 1993;25(2):
237-244.
40. Schaal K, Tafflet M, Nassif H, et al. Psychological balance in high
level athletes: gender-based differences and sport-specific patterns.
PloS One. 2011;6(5):e19007.
41. Taioli E. All causes mortality in male professional soccer players. Eur
J Public Health. 2007;17(6):600-604.
42. Von Porat A, Roos E, Roos H. High prevalence of osteoarthritis 14
years after an anterior cruciate ligament tear in male soccer players:
a study of radiographic and patient relevant outcomes. Ann Rheum
Dis. 2004;63(3):269-273.
43. Wagner J. Enhancement of athletic performance with drugs: an over-
view. Sports Med. 1991;12(4):250-265.
44. Wang G, Padmanabhan S, Wolfarth B, et al. Genomics of elite sport-
ing performance: what little we know and necessary advances. Adv
Genet. 2013;84:123-149.
45. Wen CP, Wai JPM, Tsai MK, et al. Minimum amount of physical activ-
ity for reduced mortality and extended life expectancy: a prospective
cohort study. Lancet. 2011;378(9798):1244-1253.
46. Zaidi A, Sharma S. Reduced mortality in former Tour de France par-
ticipants: the benefits from intensive exercise or a select genetic tour
de force? Eur Heart J. 2013;34(40):3106-3108.
For reprints and permission queries, please visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav
1512 Antero-Jacquemin et al The American Journal of Sports Medicine
 at INSEP on May 25, 2016ajs.sagepub.comDownloaded from 
